Navigation Links
Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
Date:4/27/2010

THE WOODLANDS, Texas, April 27 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that the company will be giving poster and oral presentations on results from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) at Digestive Disease Week (DDW) 2010 in New Orleans, Louisiana. Results from the study, in which LX1031 produced improvements in IBS symptoms, will be presented during the poster session on Sunday, May 2, 2010 from 12 p.m. to 2 p.m. Central Time and the oral presentation on Wednesday, May 5, 2010 at 9:30 a.m. CT (session start time is 8:30 a.m. CT).

DDW is the world's largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Every year it attracts approximately 16,000 physicians, researchers and academics from around the world.

Clinical development of LX1031 is being funded through a product development collaboration with Symphony Capital Partners, L.P. and its co-investors.

For more information on this program, and to access the presentations (available after May 5, 2010), please visit www.lexpharma.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1031 and the potential therapeutic and commercial potential of LX1031. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Announces Proposed $95 Million Common Stock Offering
2. Lexicon to Report Fourth Quarter and Year End 2009 Financial Results on February 23, 2010
3. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
4. Lexicon to Host Conference Call and Webcast to Review Top-Line Phase 2 Results From Diabetes Trial
5. Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
6. Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
7. Lexicon Announces Completion of Public Offering of Common Stock
8. Lexicon Announces Pricing of Common Stock in Public Offering
9. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
10. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
11. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017 FinancialBuzz.com News Commentary  ... The U.S. could see ... a new report published by New Frontier Data, the legal cannabis ... pace of cannabis legalization in the United States ... considered to be a major factor that drives growth in this ...
(Date:3/28/2017)... , March 28, 2017  Las Vegas ophthalmology practice, ... XEN45 Gel Stent (Allergan, Dublin ), ... the eye, thereby reducing intraocular pressure in patients with ... globally are affected by glaucoma that can lead to ... and blindness, if left untreated. According to ...
(Date:3/28/2017)... 28, 2017 Summary ... Digital as a Key Component of Multichannel Marketing" ... marketing landscape in the digital age. While ... provide medical advancements, it has been much slower ... relying on traditional channels and methods. However, the ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 29, 2017 , ... Hamlin Dental Group, ... is now offering laser dental treatments. Dental lasers are safe and effective options, and ... patients’ options and can improve the overall quality of care. , Dr. Hamid Reza ...
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the Microsoft Cloud expert, is ... Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating ... Ralph S. Northam and Mayor of Richmond Levar M. Stoney. , Founded in 2001, ...
(Date:3/28/2017)... ... ... For many women, getting birth control isn’t as easy as it should be. In fact, ... to a health care facility or a pharmacy within 60 minutes of where they live. ... for many who are faced with health or personal issues that leave them homebound. To ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... representatives in state legislatures and Congress to protect parental rights and civil liberties, ... and safety in America. , The demonstration coincides with a press conference taking ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... and services, is proud to announce it has joined the National Association for ... the interests of chronically ill, disabled, and dying Americans of all ages and ...
Breaking Medicine News(10 mins):